PARAGARD T 380A Drug Patent Profile

Which patents cover Paragard T 380a, and what generic alternatives are available?

Paragard T 380a is a drug marketed by Coopersurgical and is included in one NDA.

The generic ingredient in PARAGARD T 380A is copper. Two suppliers are listed for this compound. Additional details are available on the copper profile page.

Summary for PARAGARD T 380A

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PARAGARD T 380A

PARAGARD T 380A is protected by zero US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW INSERTER INTENDED TO FACILITATE SINGLE-HAND PLACEMENT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Coopersurgical	PARAGARD T 380A	copper	SYSTEM;INTRAUTERINE	018680-001	Nov 15, 1984		RX	Yes	Yes

Paragard T 380A: Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What is the market position of Paragard T 380A?

Paragard T 380A, marketed by Teva Pharmaceuticals and originally by Teva and other partners, is a hormonal-free intrauterine device (IUD). It holds a significant share of the global contraceptive market, especially in North America. As of 2022, it is one of the few copper IUDs with regulatory approval and market penetration in multiple regions.

Market size and demand

• Global contraceptive market value: Estimated at $22 billion in 2022 with a Compound Annual Growth Rate (CAGR) of 6% (MarketResearch.com, 2022).
• Copper IUD segment: Accounts for approximately 20% of the global intrauterine device market, valued at nearly $2.2 billion in 2022.
• Paragard's share: Estimated at 30-40% in North America, with lower penetration in emerging markets.

Competition landscape

• Main competitors: Copper T 380A (Paragard), GyneFix, NovaT, and other regional copper IUDs.
• Key differentiator: Paragard’s 10-year duration, established safety profile, and regulatory approvals.

What are the core patent and regulatory fundamentals?

Patent status

• Patent expiration: The original patent was filed around 1984 and expired in the U.S. in 2008.
• Secondary patents: No recent patent filings exist, exposing generic competition.

Regulatory approvals

• FDA (U.S.): Approved since 1984 for use up to 10 years.
• EMA (Europe): Approved for up to 10 years.
• Other regions: Approval status varies; China and other Asian markets approved, often with local regulatory modifications.

Reimbursement landscape

• Reimbursed by major health insurers in the U.S. and many European countries; reimbursement levels impact sales growth potential.

What are the funding and investment considerations?

Sales and revenue trends

• 2022 revenue: Estimated at $70 million in North America, with steady growth expected at 3-5% annually.
• Market share potential: Growth driven by increased awareness, healthcare provider endorsements, and expanding insurance coverage.

R&D and pipeline

• No significant R&D pipeline: Paragard is a mature product with no dedicated pipeline; growth relies on market share increase.
• Potential innovation: Opportunities include improved formulations, extended duration, or combination with hormonal agents.

Manufacturing and supply chain

• Mature manufacturing process reduces operational risk.
• Supply chain risks include raw material costs and regional regulatory changes.

What are the valuation and risk factors?

Financial valuation

• Based on historical revenues, competitive landscape, and growth rate projections, the valuation of Paragard approximates conservative multiples regarding mature drug sales.
• Market valuation of similar products ranges at 2-4x annual revenue, implying a potential valuation in the $200-$300 million range if marketed as a standalone product.

Risks

• Patent expiry and generic competition threaten market share.
• Regulatory changes, such as restrictions on copper IUDs due to safety concerns, may impact sales.
• Liability and litigation risks, although minimal due to established safety, remain.
• Reimbursement changes and healthcare policy shifts could influence sales.

Key Takeaways

• Paragard T 380A holds a significant share in North American copper IUD markets with stable revenue streams.
• Patent expiry exposes it to generic competition, limiting upside.
• Growth potential depends on broader acceptance in emerging markets and healthcare policy.
• No active pipeline dampens long-term innovation prospects.
• Market valuation aligns with mature contraceptive products, around $200-$300 million, based on current revenue estimates.

FAQs

1. How does patent expiration impact Paragard’s market exclusivity?
   Patent expiration in 2008 exposes the product to generic manufacturers, increasing competitive pressure and limiting pricing power.

2. What regional regulatory hurdles exist for expansion?
   Approval in emerging markets varies, with some requiring local clinical data or modifications, potentially delaying access.

3. What are the primary growth drivers?
   Increased awareness, higher insurance coverage, and expanding use in emerging markets.

4. What risks do legal liabilities present?
   Although safety is well-established, legal risks remain in the event of adverse events or claims related to contraindications.

5. How does market size influence investment returns?
   A limited but stable market in North America minimizes upside but offers reliable cash flow, while growth prospects in emerging markets could unlock higher returns.

---

Sources:

1. MarketResearch.com. (2022). Global contraceptive market report.
2. FDA. (1984). Paragard T 380A approval documentation.
3. EMA. (2022). Regulatory decision summary for copper IUDs.
4. Teva Pharmaceutical Annual Reports. (2022). Financial performance and product pipeline.
5. U.S. Patent and Trademark Office. Patent expiration timelines for Paragard.

Note: Data and estimates are based on publicly available industry reports and regulatory disclosures as of early 2023.